Actionable news
All posts from Actionable news
Actionable news in LOXO: LOXO ONCOLOGY INC,

Loxo Oncology Prices Follow-On Offering Of Common Stock STAMFORD, Conn.

The following excerpt is from the company's SEC filing.

, November 11, 2015 Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the pricing of its underwritten public offering of 2,500,000 shares of common stock at a public offering price of $26.50 per share. Gross proceeds to Loxo Oncology from this offering are expected to be approximately $66.3 million. Loxo Oncology intends to use the net proceeds from this offering for general corporate purposes, which may include funding research and development, increasing its working capital, acq uisitions or investments in businesses, products or technologies that are complementary to its own, and capital expenditures.

Loxo Oncology also has granted the underwriters a

30-day option to purchase up to an additional 375,000 shares of its common stock offered in the public offering, solely to cover over-allotments, if any, at the public offering price less the underwriting discounts and commissions. All of the shares will be offered and sold by Loxo Oncology.

The offering is expected to close on November 17, 2015, subject to customary closing conditions. Citigroup Global Markets Inc. and Cowen and Company, LLC are acting as the joint book-running managers for the offering. Stifel is acting as joint lead manager, and Oppenheimer & Co. Inc. and Trout Capital LLC are acting as co-managers.

The public offering is being made pursuant to a shelf registration statement on Form S-3 that was filed by Loxo Oncology with the Securities and Exchange Commission (SEC) on August 3, 2015 and declared effective by the SEC on August 11, 2015. A final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and...